Teva Pharmaceutical Industries (NYSE:TEVA) shares continued gains for seven straight sessions, as the stock closed 1% higher ...

Senores Pharmaceuticals acquires two ANDAs from Teva Pharmaceuticals USA Inc., expanding its US market presence.

Teva Pharmaceuticals has received US FDA approval for AJOVY (fremanezumab-vfrm) as a preventive treatment for episodic migraine in children and adolescents aged 6–17 who weigh at least 45 kilograms.

Ahmedabad: Senores Pharmaceuticals Limited, through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA, has ...

PureTech Health has launched a subsidiary company – Celea Therapeutics – with the task of taking an experimental drug for ...

PureTech's latest spinoff Celea Therapeutics was created to progress the former's lead respiratory IPF programme, ...

Senores Pharmaceuticals rose 2.16% to Rs 687.75 after its US arm signed a deal to acquire two USFDA-approved ANDAs from Teva Pharmaceuticals USA, targeting a market size of up to $120 million.

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Corcept Therapeutics’ second quarter was marked by continued sales growth in its core endocrinology franchise, with ...

Using its hub-and-spoke business model, PureTech is launching a new company to develop deupirfenidone (LYT-100), its ...

The spinout, known as Celea Therapeutics, will advance what’s designed to be an improved version of the drug pirfenidone for ...

Half Year Results/Half Year ReportFormycon confirms full-year guidance following business development in line with plan – working capital raised 13.08.2025 / 06:30 CET/CESTThe issuer is solely ...